A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers

NCT01248052 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Disorder

Interventions

DRUG: LY2979165
DRUG: Placebo

Sponsor

Eli Lilly and Company